An 86% objective response rate in a Phase 1 trial gets attention in any context, but the setting here sharpens the stakes considerably: LYMPHIR (denileukin diftitox-cxdl), approved in August 2024 for relapsed or refractory cutaneous T-cell lymphoma, is generating early signals well outside that indication. Data presented at the 2026 ASTCT and CIBMTR Tandem Meetings showed that LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphomaB-cell lymphoma produced an 86% overall response rate, including 57% complete responses, with no dose-limiting toxicities observed. Separately, ASCO data from an investigator-initiated trial in recurrent or refractory gynecologic malignancies showed a 24% ORR, a 48% clinical benefit rate, and a median progression-free survival of 20.5 months among patients achieving clinical benefit. Neither readout reflects a company-sponsored pivotal program yet, but together they define where Citius Oncology is building its scientific narrative beyond CTCL.
The commercial story, though modest in absolute scale, is directionally cleaner than the financials suggest at first glance. LYMPHIR generated $7.1 million in revenue for the first nine months of fiscal 2026, with a 77% gross margin for that period. Institutional vial orders grew 31% quarter over quarter, new institutions ordering jumped 80%, and July set a record with 383 vials ordered. The company also reports no reimbursement denials or preauthorization barriers to date, which matters because formulary resistance is often where early oncology launches stall. The commercial team, now 29 professionals deployed nationwide through EVERSANA, reached full coverage only in August, so the third-quarter numbers reflect a structurally smaller force than is now in place. That lag creates a meaningful mismatch between the revenue recognized and the capacity currently deployed.
The financial picture carries real tension. Cash stood at $17.0 million as of June 30, 2026, supported by a $4.5 million registered direct offering in April, roughly $9.7 million from warrant exercises, and the first $10.0 million tranche of a senior secured term loan of up to $25.0 million. General and administrative expenses ballooned to $38.3 million for the nine-month period, though $19.7 million of that reflects a non-recurring contract cancellation charge from March. Strip that out and the underlying burn rate is more manageable, though still significantly outpacing revenue. The approved indication in relapsed or refractory CTCL anchors the business, but the cash position demands that institutional uptake accelerates, not just directionally but on a schedule the current runway can tolerate.
The metric to watch closely is the monthly institutional vial order trend. July’s record 383 vials is the first post-expansion-team data point, and whether August and September sustain or accelerate that pace will determine whether the commercial build is generating returns fast enough to close the gap between gross margin and operating losses before Citius needs to access additional capital.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
